Rna-Loaded Dendritic Cell Vaccine
Malignant Neoplasms Brain
Gary Archer Ph.D.vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
36 Active assets in the Malignant Neoplasms Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan University of California, Davis | Phase 2 | BBB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Sorafenib Virginia Commonwealth University | Phase 2 | BB |
Cyclophosphamide Essen Biotech | Phase 2 | BB |
DIANHYDROGALACTITOL Kintara Therapeutics, Inc. | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →